These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Omalizumab: a review of its use in the management of allergic asthma. Bang LM; Plosker GL Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177 [TBL] [Abstract][Full Text] [Related]
24. Anti-IgE for chronic asthma in adults and children. Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491 [TBL] [Abstract][Full Text] [Related]
25. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update. D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196 [TBL] [Abstract][Full Text] [Related]
26. Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review. Bush RK Treat Respir Med; 2004; 3(1):45-57. PubMed ID: 15174893 [TBL] [Abstract][Full Text] [Related]
27. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898 [TBL] [Abstract][Full Text] [Related]
28. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. D'Amato G Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445 [TBL] [Abstract][Full Text] [Related]
29. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353 [TBL] [Abstract][Full Text] [Related]
30. Rhinovirus-Induced Cytokine Alterations With Potential Implications in Asthma Exacerbations: A Systematic Review and Meta-Analysis. Liew KY; Koh SK; Hooi SL; Ng MKL; Chee HY; Harith HH; Israf DA; Tham CL Front Immunol; 2022; 13():782936. PubMed ID: 35242128 [TBL] [Abstract][Full Text] [Related]
31. Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE. Heymann PW; Platts-Mills TAE; Woodfolk JA; Borish L; Murphy DD; Carper HT; Conaway MR; Steinke JW; Muehling L; Gerald Teague W; Kennedy JL; Irani AM; McGraw MD; Early SV; Wheatley LM; Adams AP; Turner RB J Allergy Clin Immunol; 2020 Sep; 146(3):545-554. PubMed ID: 32018030 [TBL] [Abstract][Full Text] [Related]
32. Multi-season analyses of causative pathogens in children hospitalized with asthma exacerbation. Abe N; Yasudo H; Fukano R; Nakamura T; Okada S; Wakiguchi H; Okazaki F; Shirabe K; Toda S; Okamoto R; Ouchi K; Ohga S; Hasegawa S Pediatr Allergy Immunol; 2019 Nov; 30(7):724-731. PubMed ID: 31251831 [TBL] [Abstract][Full Text] [Related]
33. Most commonly isolated viruses in asthma exacerbation and their correlation with eosinophil and total serum immunoglobulin E levels. Robledo Aceves M; Barrón Balderas A; Jaime Ornelas ML Arch Argent Pediatr; 2018 Jun; 116(3):192-197. PubMed ID: 29756703 [TBL] [Abstract][Full Text] [Related]
34. Role of viruses in asthma. Jartti T; Bønnelykke K; Elenius V; Feleszko W Semin Immunopathol; 2020 Feb; 42(1):61-74. PubMed ID: 31989228 [TBL] [Abstract][Full Text] [Related]
35. [Application of humanized Anti-IgE antibodies (omalizumab). A new principle in the treatment of allergic diseases in ENT medicine]. Pfaar O; Klimek L HNO; 2007 Dec; 55(12):981-90; quiz 991-2. PubMed ID: 17992493 [TBL] [Abstract][Full Text] [Related]
36. Does anti-IgE therapy help in asthma? Efficacy and controversies. Avila PC Annu Rev Med; 2007; 58():185-203. PubMed ID: 17059361 [TBL] [Abstract][Full Text] [Related]
38. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Holgate S; Smith N; Massanari M; Jimenez P Allergy; 2009 Dec; 64(12):1728-36. PubMed ID: 19839977 [TBL] [Abstract][Full Text] [Related]
39. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232 [TBL] [Abstract][Full Text] [Related]
40. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal. Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]